T
VKTX icon

Tidemark’s Viking Therapeutics VKTX Stock Holding History

Tidemark’s Portfolio VKTX Stock Details VKTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$3.35K Hold
86
– – ﹤0.01% 641
2026
Q1 		$2.8K Hold
86
– – ﹤0.01% 626
2025
Q4 		$3.02K Hold
86
– – ﹤0.01% 551
2025
Q3 		$2.26K Hold
86
– – ﹤0.01% 589
2025
Q2 		$2.28K Hold
86
– – ﹤0.01% 592
2025
Q1 		$2.08K Hold
86
– – ﹤0.01% 613
2024
Q4 		$3.46K Hold
86
– – ﹤0.01% 554
2024
Q3 		$5.45K Buy
+86
New +$5.05K ﹤0.01% 483

Other funds holding VKTX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $495B AUM 43.24% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
American Century Companies
American Century Companies Kansas City, Missouri $226B AUM 44.75% 1-Year Est. Return

Tidemark's VKTX Position: Q2 2026 in Review

Tidemark held its Viking Therapeutics (VKTX) position steady in Q2 2026 at 86 shares worth $3.35K. The position accounts for ﹤0.01% of the portfolio, ranked #641.

Tidemark first reported a position in VKTX in Q3 2024 and has held it in 8 quarters since. The position peaked at $5.45K in Q3 2024. 434 funds tracked by Wall St. Rank hold VKTX as of Q2 2026.

  • Tidemark held 86 shares of Viking Therapeutics worth $3.35K as of Q2 2026.
  • Tidemark left its Viking Therapeutics share count unchanged in Q2 2026.
  • Viking Therapeutics made up ﹤0.01% of Tidemark's portfolio in Q2 2026, its #641 holding.
  • Tidemark first reported a position in Viking Therapeutics in Q3 2024 and has held it in 8 quarters since.
  • Tidemark's Viking Therapeutics position peaked at $5.45K in Q3 2024.
  • 434 funds tracked by Wall St. Rank held Viking Therapeutics as of Q2 2026.

Based on Tidemark's 13F filing for Q2 2026, filed 10 Aug 2026.